Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Fiona Craig

Mon, August 17, 2026 at 3:28 PM GMT+3 2 min read

• CTOR +10.04%

Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.05% in pre-market trading on Monday after the company reported fiscal third-quarter results that fell well short of analyst expectations, despite signs of increasing institutional demand for LYMPHIR.

Quarterly revenue came in at $1.5 million, substantially below the consensus estimate of $12.52 million. Revenue nevertheless improved from zero in the same period last year as the commercial rollout of LYMPHIR continued.

The company reported a loss of $0.34 per share, compared with analysts' expectations for earnings of $0.03 per share.

For the nine months ended June 30, 2026, Citius Oncology generated total revenue of $7.1 million.

LYMPHIR institutional orders continue to accelerate

Commercial indicators for LYMPHIR showed further progress during the third quarter, with institutional vial orders increasing 31% sequentially to 926 from 708 in the previous quarter.

Momentum continued into July, when institutions ordered 383 vials. That represented a 25% increase over the average monthly order volume recorded during the prior quarter and marked the strongest month since the product's launch.

Citius Oncology said 44 institutions have now prescribed and ordered LYMPHIR. The number of new ordering institutions increased 80% compared with the previous quarter.

"Institutional demand is accelerating," said Leonard Mazur, Chairman and Chief Executive Officer. "The positive trajectory of formulary approvals, institutional adoption, and unit demand gives us confidence in a robust remainder of the fiscal year."

Commercial infrastructure expands alongside product rollout

Citius Oncology continued investing in its commercial capabilities during the quarter as it seeks to broaden adoption of LYMPHIR.

The company expanded its commercial organisation by adding 21 field-based professionals as well as eight medical science liaisons.

It also reported achieving near-universal payer coverage, with no reimbursement denials or prior-authorisation barriers recorded to date.

The combination of broader institutional adoption, expanding field coverage and improved formulary access is intended to support further growth in LYMPHIR sales through the remainder of the fiscal year.

Higher commercial spending widens quarterly loss

The investment required to support the launch contributed to a substantial increase in operating expenses.

Operating costs reached $9.7 million during the quarter, compared with $4.9 million in the corresponding period last year, with the increase primarily reflecting the expansion of the company's commercial operations.

Citius Oncology reported a quarterly net loss of $8.9 million, or $0.08 per share, widening from a loss of $5.4 million, or $0.08 per share, in the prior-year period.

The company finished the quarter with cash and cash equivalents of $16.6 million as of June 30, 2026.

While the significant revenue miss weighed heavily on the shares, increasing vial orders and a growing number of prescribing institutions indicate that LYMPHIR's commercial rollout is gaining traction. Investors will now be watching whether that adoption translates into a stronger revenue contribution over the remainder of the fiscal year.

Citius Oncology stock price